Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Myov save search
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
Published: 2022-03-07 (Crawled : 18:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.08%
H: 2.05%
C: -5.15%
uro-902 phase 2 pos gene therapy trial potential topline results positive therapy results topline phase 2b
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Published: 2022-02-25 (Crawled : 14:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
orgovyx treatment prostate cancer state positive cancer chmp
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Published: 2021-11-08 (Crawled : 14:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -2.69%
H: 0.83%
C: -0.96%
blood positive results bladder
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: -7.06%
blood heart positive bladder
Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
Published: 2021-08-04 (Crawled : 17:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.77%
H: 3.56%
C: -2.29%
positive
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Published: 2021-05-21 (Crawled : 13:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.71%
H: 4.69%
C: 1.59%
treatment positive women chmp
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-03-24 (Crawled : 11:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.34%
H: 1.27%
C: 0.37%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 1.17%
C: -7.12%
positive therapy women phase 3
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2021-01-26 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.03%
H: 0.89%
C: 0.11%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 4.44%
H: 9.52%
C: 4.67%
positive therapy phase 3
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Published: 2020-05-29 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer positive phase 3 prostate cancer cardio cardiovascular
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2020-06-23 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy positive results positive results phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.